World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
87
Citations
33870
World Ranking
13500
National Ranking
6865

Gini F. Fleming publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Gini F. Fleming sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 432 publications — 45th percentile

45% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Gini F. Fleming D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Gini F. Fleming sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 87 D-Index — 34th percentile

34% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Gini F. Fleming is affiliated with the University of Chicago in the United States. Their research spans multiple areas within medicine, focusing predominantly on oncology and biochemistry, genetics, and molecular biology. Fleming has contributed extensively to the fields of oncology, reproductive medicine, pulmonary and respiratory medicine, cancer research, and obstetrics and gynecology.

Their main topics of research include ovarian cancer diagnosis and treatment, endometrial and cervical cancer treatments, breast cancer treatment studies, estrogen and related hormone effects, cancer immunotherapy and biomarkers, advanced breast cancer therapies, and PARP inhibition in cancer therapy.

Fleming's frequent publication venues highlight a concentration in clinical oncology and gynecologic oncology, with numerous articles published in the following journals:

  • Journal of Clinical Oncology
  • Gynecologic Oncology
  • Cancer Research
  • Annals of Oncology
  • Breast Cancer Research and Treatment

The following papers are among the recent publications associated with Fleming, demonstrating involvement in clinical trials and translational cancer research:

  • Updates and New Options in Advanced Epithelial Ovarian Cancer Treatment (2020), published in Obstetrics and Gynecology
  • Carboplatin and Paclitaxel for Advanced Endometrial Cancer: Final Overall Survival and Adverse Event Analysis of a Phase III Trial (NRG Oncology/GOG0209) (2020), published in Journal of Clinical Oncology
  • Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial (2021), published in The Lancet
  • Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials (2022), published in Journal of Clinical Oncology
  • Epigenetic priming enhances antitumor immunity in platinum-resistant ovarian cancer (2022), published in Journal of Clinical Investigation

Fleming has collaborated frequently with several researchers, including Rita Nanda, Olufunmilayo I. Olopade, Meredith M. Regan, Prudence A. Francis, and John W. Moroney, indicating a strong network within clinical and translational oncology research.

Best Publications

  • Incorporation of bevacizumab in the primary treatment of ovarian cancer

    Robert A. Burger;Mark F. Brady;Michael A. Bookman;Gini F. Fleming

  • Improved Outcomes From Adding Sequential Paclitaxel but Not From Escalating Doxorubicin Dose in an Adjuvant Chemotherapy Regimen for Patients With Node-Positive Primary Breast Cancer

    I. Craig Henderson;Donald A. Berry;George D. Demetri;Constance T. Cirrincione

  • Postmastectomy Radiotherapy: Clinical Practice Guidelines of the American Society of Clinical Oncology*

    Abram Recht;Stephen B. Edge;Lawrence J. Solin;David S. Robinson

  • UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity

    L Iyer;S Das;L Janisch;M Wen

  • Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer

    Olivia Pagani;Meredith M. Regan;Barbara A. Walley;Gini F. Fleming

  • Adjuvant ovarian suppression in premenopausal breast cancer

    Prudence A. Francis;Prudence A. Francis;Meredith M. Regan;Gini F. Fleming;István Láng

  • Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer

    Robert L. Coleman;Gini F. Fleming;Mark F. Brady;Elizabeth M. Swisher

  • Phase II Clinical Trial of Bevacizumab and Low-Dose Metronomic Oral Cyclophosphamide in Recurrent Ovarian Cancer: A Trial of the California, Chicago, and Princess Margaret Hospital Phase II Consortia

    Agustin A. Garcia;Hal Hirte;Gini Fleming;Dongyun Yang

  • Phase III Trial of Doxorubicin Plus Cisplatin With or Without Paclitaxel Plus Filgrastim in Advanced Endometrial Carcinoma: A Gynecologic Oncology Group Study

    Gini F. Fleming;Virginia L. Brunetto;David Cella;Katherine Y. Look

  • Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study

    Joyce F. Liu;William T. Barry;Michael Birrer;Jung Min Lee

  • Barriers to Clinical Trial Participation by Older Women With Breast Cancer

    M. Margaret Kemeny;Bercedis L. Peterson;Alice B. Kornblith;Hyman B. Muss

  • Intensity-modulated whole pelvic radiotherapy in women with gynecologic malignancies.

    Arno J Mundt;Anthony E Lujan;Jacob Rotmensch;Steven E Waggoner

  • Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer.

    P. A. Francis;P. A. Francis;O. Pagani;G. F. Fleming;B. A. Walley

  • Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors.

    Jason J. Luke;Jeffrey M. Lemons;Theodore G. Karrison;Sean P. Pitroda

  • Current recommendations and recent progress in endometrial cancer.

    Rebecca A. Brooks;Rebecca A. Brooks;Gini F. Fleming;Ricardo R. Lastra;Nita K. Lee

  • Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial

    Kathleen N Moore;Angeles Alvarez Secord;Melissa A Geller;David Scott Miller

  • Postmastectomy Radiotherapy: An American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Focused Guideline Update

    Abram Recht;Elizabeth A. Comen;Richard E. Fine;Gini F. Fleming

  • Failure of Higher-Dose Paclitaxel to Improve Outcome in Patients With Metastatic Breast Cancer: Cancer and Leukemia Group B Trial 9342

    Eric P. Winer;Donald A. Berry;Susan Woolf;David Duggan

  • Final overall survival of a randomized trial of bevacizumab for primary treatment of ovarian cancer

    Krishnansu S. Tewari;Robert A. Burger;Danielle Enserro;Barbara M. Norquist

  • Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study.

    Gini F. Fleming;Michael W. Sill;Michael W. Sill;Kathleen M. Darcy;D. Scott McMeekin

Frequent Co-Authors

Mark J. Ratain
Mark J. Ratain University of Chicago
Amit M. Oza
Amit M. Oza Princess Margaret Cancer Centre
Ursula A. Matulonis
Ursula A. Matulonis Harvard University
Michael J. Birrer
Michael J. Birrer University of Arkansas for Medical Sciences
Meredith M. Regan
Meredith M. Regan Harvard University
Alan S. Coates
Alan S. Coates University of Sydney
Olufunmilayo I. Olopade
Olufunmilayo I. Olopade University of Chicago
Bradley J. Monk
Bradley J. Monk University of Arizona
Richard D. Gelber
Richard D. Gelber Harvard University
Theodore Karrison
Theodore Karrison University of Chicago

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a future in medicine doesn’t always mean attending traditional, on-campus programs. For those interested in nursing, there are several flexible options, such as the cheapest bsn programs available online. These programs provide an affordable pathway for registered nurses seeking career advancement without the financial strain.

Not from a nursing background? Opportunities still exist through direct entry msn programs for non-nursing majors online, allowing those with different undergraduate degrees to shift into nursing quickly.

Applicants concerned about admissions requirements should consider some of the easiest nursing schools to get into, which can help streamline entry into competitive healthcare fields.

For those seeking careers outside of direct patient care, medical billing and coding online schools offer accredited training opportunities with financial aid, preparing graduates for essential roles in healthcare administration.

Best Scientists Citing Gini F. Fleming

Trending Scientists

Recently Published Articles